REG - Aptamer Group PLC - Notification of dealings by a director/PDMR

AptamerAnnouncement

19/12/2024 16:45

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20241219:nRSS8247Qa&default-theme=true

RNS Number : 8247Q  Aptamer Group PLC  19 December 2024

 

19 December 2024

 

Aptamer Group plc

 

("Aptamer", the "Company" or the "Group")

 

Notification of dealings by a director/PDMR

 

Aptamer Group plc (AIM: APTA), the developer of novel Optimer(®) binders to
enable innovation in the life sciences industry, today announces that David
Bunka, Chief Scientific Officer, on 19 December 2024 purchased 1,317,870
ordinary shares of £0.001 each ("Ordinary Shares") in the Company at a price
of 0.3794 pence per Ordinary Share.

 

Following this transaction, David Bunka's total beneficial interest in the
Company is 19,842,070 Ordinary Shares, representing approximately 1.00% of the
Company's issued share capital.

 

The following disclosures are made in accordance with the requirements of the
UK Market Abuse Regulation and provide detail in relation to the purchase of
ordinary shares by directors and other PDMRs in the Company.

 

NOTIFICATIONS AND PUBLIC DISCLOSURE OF TRANSACTIONS BY PERSONS DISCHARGING
MANAGERIAL RESPONSIBILITIES AND PERSONS CLOSELY ASSOCIATED WITH THEM

 

 1    Details of the person discharging managerial responsibilities / person closely

    associated

 a)   Name                                                         David Bunka

 2    Reason for the notification

 a)   Position/status                                              Chief Scientific Officer

 b)   Initial notification /Amendment                              Initial notification

 3    Details of the issuer, emission allowance market participant, auction

    platform, auctioneer or auction monitor

 a)   Name                                                         Aptamer Group plc

 b)   LEI                                                          213800Y4XGH3WJNBE686

 4    Details of the transaction(s): section to be repeated for (i) each type of

    instrument; (ii) each type of transaction; (iii) each date; and (iv) each
      place where transactions have been conducted

 a)   Description of the financial instrument, type of instrument  Ordinary shares of £0.001 each

      Identification code                                          GB00BNRRP542

 b)   Nature of the transaction                                    Purchase of shares

 c)   Price(s) and volume(s)                                       Price 0.3794p

                                                                   Volume 1,317,870
 d)   Aggregated information

      - Aggregated volume                                          1,317,870
      - Price                                                      0.3794p

 e)   Date of the transaction                                      19 December 2024

 f)   Place of the transaction                                     London Stock Exchange

 

- Ends -

 

For further information, please contact:

 

 Aptamer Group plc                                        +44 (0) 1904 217 404

 Arron Tolley, Chief Executive Officer
 SPARK Advisory Partners Limited - Nominated Adviser      +44 (0) 20 3368 3550

 Andrew Emmott / Adam Dawes
 Turner Pope Investments (TPI) Limited - Broker           +44 (0) 20 3657 0050

 James Pope / Andrew Thacker
 Northstar Communications Limited - Investor Relations    +44 (0) 113 730 3896

 Sarah Hollins

 

This announcement contains inside information for the purposes of the UK
Market Abuse Regulation.

 

About Aptamer Group plc

 

Aptamer Group is a leading global developer of aptamer-based ligands that help
scientists remove the limits to discovery and innovation. Leveraging a
proprietary discovery and development platform, Aptamer delivers custom
affinity ligands, supported with a complete suite of characterisation and
validatory assays that enhance the translation of its binders and optimise
scientific outcomes for customers.

 

Aptamer's cutting-edge technology spans healthcare, research, personal care,
and industrial processes, delivering new affinity solutions for novel targets,
advanced diagnostics, and precision therapies. By working with industry
leaders in pharmaceutical, biotechnology, personal health, academic, and
clinical research sectors, Aptamer is accelerating science through the custom
development of tools and therapies.

 

To register for news alerts by email go to
https://aptamergroup.com/investors/investor-news-email-alerts/
(https://aptamergroup.com/investors/investor-news-email-alerts/) .

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  DSHTLBFTMTIBBJI